A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
2022-06-27
عنوان الدراسة
A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
داعم الدراسة
Astrazeneca
دواء الدراسة
Trastuzumab-deruxtecan (Enhertu)
رقم بروتوكول الدراسة
D967UC00001
حالة الدراسة
Ongoing
موقع الدراسة
King Fahad Specialist Hospital (Dammam)
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。